Skip to main content

Assoc. Prof. Cengiz Dibekoğlu, MD

General Surgeon · Laparoscopic · Robotic · Oncologic Surgery

Clinical trials explorer

Filter by cancer type, molecular target, phase, and recruitment status.

← Module home

Loading filters…

Scientific discovery dossierExperimental discoveries

RAS(ON) tri-complex pharmacology — preclinical discovery basis

Pancreas · Multiple / solid tumors

Discovery dossier: RAS(ON) preclinical concept underpinning clinical programs — not a care standard.

Experimental models: Cell lines and animal models (clinical translation is on separate cards).

Translational distance: Human clinical benefit cannot be inferred here. Clinical: RMC-6236-001, RASolute 302, elironrasib/daraxonrasib.

Not a clinical trial or treatment option.

Discovery dossierPrimary source
Scientific discovery dossierExperimental discoveriesDOI 10.1002/anie.202317578

Photo-controlled calcium storm — Ca²⁺ overload in tumor cells

Multiple / solid tumors

Discovery dossier: light-triggered endogenous Ca²⁺ storm. No human clinical efficacy evidence.

Experimental models: Tumor cell cultures; injectable HA-coated mesoporous silica nanomodulator; tumor regression after NIR irradiation reported in tumor-bearing mice.

Translational distance: Not a human clinical trial or approved therapy. Selectivity, systemic toxicity, and translation into surgical oncology practice are unproven.

Not a clinical trial or treatment option.

Discovery dossierPrimary source
Scientific discovery dossierExperimental discoveriesDOI 10.1016/j.bbamcr.2014.02.012

SOCE / STIM1–ORAI1 — apoptotic resistance in pancreatic adenocarcinoma

Pancreas

Discovery dossier: STIM1/ORAI1 SOCE contributes to apoptotic resistance in PDAC cells — not a clinical test.

Experimental models: Pancreatic adenocarcinoma cell lines / in vitro SOCE measurements.

Translational distance: Not a validated clinical predictive test or approved drug target. Does not change surgical/adjuvant decisions.

Not a clinical trial or treatment option.

Discovery dossierPrimary source
Scientific discovery dossierExperimental discoveriesDOI 10.21037/tcr-2024-2563

SOCE_Score — research biomarker (neuroblastoma RNA-seq)

Multiple / solid tumors

Discovery dossier: SOCE_Score studied in neuroblastoma datasets — not a clinic-validated predictive test.

Experimental models: Multiple neuroblastoma RNA-seq datasets; claimed validation across cohorts; CMap drug-repurposing hypothesis.

Translational distance: Not a GI surgical oncology standard. Must not be presented as an approved predictive test. Needs medical review.

Not a clinical trial or treatment option.

Discovery dossierPrimary source
Scientific discovery dossierExperimental discoveriesDOI 10.1002/emmm.201302989

STIM1/STIM2 — CD8+ T-cell antitumor immunity

Multiple / solid tumors

Discovery dossier: SOCE is critical for CD8+ antitumor immunity — not a human treatment protocol.

Experimental models: Conditional knockout mice; in vivo tumor-immunity experiments.

Translational distance: Generates immunotherapy-combination hypotheses; no clinical SOCE-inhibitor indication.

Not a clinical trial or treatment option.

Discovery dossierPrimary source
Scientific discovery dossierExperimental discoveriesDOI 10.1016/j.biopha.2022.114074

TRP channels, calcium homeostasis, and metastasis — discovery dossier

Multiple / solid tumors

Discovery dossier (not one NCT): TRP–Ca²⁺–metastasis links are cancer-type specific; no claim that organ metastasis is ‘solved’.

Experimental models: Cell migration/invasion; xenograft/experimental metastasis mouse models; clinical cohort correlations (correlation ≠ causation).

Translational distance: A composite of multiple papers — not one clinical trial. Does not claim organ-specific metastasis mechanisms are fully solved.

Not a clinical trial or treatment option.

Discovery dossierPrimary source
Research areaEmerging treatment technologiesPriority: very high

Personalized mRNA cancer vaccines

Melanoma · Pancreas · Multiple / solid tumors

Research area: personalized mRNA vaccines. KEYNOTE-942, V940 phase III, and pancreas vaccine cards are listed separately underneath.

Evidence level: Randomized phase IIb results in melanoma plus phase III confirmation trials; early clinical in pancreas.

Not a single trial · 3 linked records

Area dossier
Research areaEmerging treatment technologiesPriority: very high

PROTACs — targeted protein degradation

Pancreas · Multiple / solid tumors

Research area: protein degradation. Setidegrasib (KRAS G12D) clinical card underneath; separate from classic inhibitor cards.

Evidence level: 2026 phase I clinical activity signal for KRAS G12D degrader setidegrasib (ASP3082) in NEJM; not standard care.

Not a single trial · 1 linked records

Area dossier
Research areaEmerging treatment technologiesPriority: very high

Bispecific antibody–drug conjugates (BsADCs)

Gastric / esophageal · Biliary tract · Multiple / solid tumors

Research area: BsADCs. BL-B01D1 esophagus/biliary phase III cards underneath; zanidatamab is not an ADC.

Evidence level: Some molecules in phase III / regional programs; izalontamab brengitecan (BL-B01D1) as an example. Not all BsADCs are equivalent.

Not a single trial · 2 linked records

Area dossier
Research areaEmerging treatment technologiesPriority: high

Armored CAR-T — solid tumors

Multiple / solid tumors

Research area: armored CAR-T. Early-phase ARMADA example underneath; do not conflate with hematologic CAR-T.

Evidence level: Mostly early clinical (phase I) in solid tumors. Hematologic CAR-T success does not automatically transfer.

Not a single trial · 1 linked records

Area dossier
AppointmentWhatsAppMessageTumor boardRequest